A PROSPECTIVE, SINGLE-CENTERED, ASSESSOR-BLINDED STUDY TO EVALUATE THE CLINICAL EFFICACY OF THE PROPOSED CELL/TISSUE HISTOPATHOLOGY PROCESSOR CCELL (CONFOCAL FLUORESCENCE ENDOMICROSCOPY) FOR INTRAOPERATIVE DIAGNOSIS IN BRAIN TUMORS

Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorVPIX Medical

About this trial

The primary objective of this single-center study is to demonstrate the performance of cCeLL, used in real time, compared to frozen section analysis. The investigational device is intended for use with indocyanine green (ICG) for fluorescence imaging as an aid in the visualization of vessels (micro- and macro-vasculature) blood flow in the cerebrovascular before, during or after cranial diagnostic and therapeutic procedures, such as tumor biopsy and resection, and the images will be immediately transmitted to a single pathologist for real-time evaluation, without influencing the surgical decision-making process. The comparison will be made between the device and the conventional intraoperative histological frozen section analysis of identical brain tissue samples in the same patient. Both methods will be compared in terms of their accuracy using the standard of practice, the final pathological diagnosis.

Eligibility criteria

Qualifiers

Male or female patients aged 18 years or older as of the screening date

Patients suspected of having a brain tumor who are scheduled for neurosurgery and are considered candidates for tumor resection

Patients who understand and have signed the informed consent form

Disqualifiers

Specimens obtained from patients who have agreed to participate in this clinical trial and who meet the inclusion criteria

Normal tissue specimens obtained unavoidably during tumor resection surgery in tumor patients

Tissue samples must be adequate for both FS and PS analysis

Minimum lesion size of 1 cm for reliable cCeLL imaging

Trial design

Treatments tested in this trial

  • cCeLL In vivo
  • Indocyanine Green

Treatment groups

30 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators